Important Notice - Join me at Chimera Research Group
First, thank you for visiting and supporting BiotechDueDiligence, it is a great pleasure to maintain this site and interact with so many of you via my blog, email, Twitter, and phone. It has been very humbling to learn that the hard work that I put into researching and analyzing biotechnology and pharmaceutical stocks is of interest and utility to so many talented individual investors, professional money managers, analysts, journalists, and scientists.
I recently accepted an offer to join Chimera Research Group, an biopharmaceutical research firm dedicated to providing independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis. This opportunity will allow me to further my personal and professional development that has included my work here on BiotechDueDiligence.
This site will continue as a free resource to all those interested in biotech investing. However, certain features, such as detailed stock or catalyst analysis articles, and commentary on investor webcasts and earnings conference call presentations will be predominantly directed towards the efforts of Chimera Research Group. If you have found these sorts of posts valuable in the past, I hope that you will continue to follow and support my work at Chimera. Any links on the BiotechDueDiligence site to articles that require a Chimera subscription will be clearly indicated in blue. Start your membership today and get access to all of the reports and trade ideas from the entire Chimera team.
My real-time quips, reactions, trade notes, news links, and commentary will appear as always on my Twitter feed @BioDueDiligence. You can also stay informed of all the newest updates to the BiotechDueDiligence site by signing up for the email newsletter. If you have any other questions or comments, please feel free to contact me.
I recently accepted an offer to join Chimera Research Group, an biopharmaceutical research firm dedicated to providing independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis. This opportunity will allow me to further my personal and professional development that has included my work here on BiotechDueDiligence.
This site will continue as a free resource to all those interested in biotech investing. However, certain features, such as detailed stock or catalyst analysis articles, and commentary on investor webcasts and earnings conference call presentations will be predominantly directed towards the efforts of Chimera Research Group. If you have found these sorts of posts valuable in the past, I hope that you will continue to follow and support my work at Chimera. Any links on the BiotechDueDiligence site to articles that require a Chimera subscription will be clearly indicated in blue. Start your membership today and get access to all of the reports and trade ideas from the entire Chimera team.
My real-time quips, reactions, trade notes, news links, and commentary will appear as always on my Twitter feed @BioDueDiligence. You can also stay informed of all the newest updates to the BiotechDueDiligence site by signing up for the email newsletter. If you have any other questions or comments, please feel free to contact me.